Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography (Q41456415)

30 September 2017

Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

30 September 2017

1 reference

1 reference

Erratum: Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration-Controlled Transient Elastography.

inferred from title

corrigendum / erratum

1 reference

12 July 2019

http://api.crossref.org/works?select=update-to&filter=doi:10.1038/AJG.2016.14

Nezam H Afdhal

4

0 references

author name string

Elliot B Tapper

1

1 reference

30 September 2017

Neil Sengupta

2

1 reference

30 September 2017

M G Myriam Hunink

3

1 reference

30 September 2017

Michelle Lai

5

1 reference

30 September 2017

language of work or name

English

0 references

publication date

25 August 2015

1 reference

The American Journal of Gastroenterology

30 September 2017

1 reference

30 September 2017

110

1 reference

30 September 2017

9

1 reference

30 September 2017

1298-1304

1 reference

Management of nonalcoholic fatty liver disease: a 60-year-old man with probable nonalcoholic fatty liver disease: weight reduction, liver biopsy, or both?

30 September 2017

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.241

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.241

Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.241

Burden of gastrointestinal disease in the United States: 2012 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.241

Cost-effectiveness of ultrasound-guided liver biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.241

Management of chronic hepatitis C: clinical audit of biopsy based management algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.241

Sampling variability of liver fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.241

Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.241

Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.241

The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.241

FibroScan (vibration-controlled transient elastography): where does it stand in the United States practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.241

Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.241

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.241

The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.241

Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.241

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.241

Simple non-invasive biomarkers of advanced fibrosis in the evaluation of non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.241

Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.241

Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.241

Ultrasound elastography for fibrosis surveillance is cost effective in patients with chronic hepatitis C virus in the UK

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.241

Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.241

A health technology assessment of transient elastography in adult liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.241

Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.241

Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.241

Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.241

Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2015.241

Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting

21 January 2018

1 reference

12 December 2020

Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease

1 reference

12 December 2020

The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD

1 reference

12 December 2020

1 reference

12 December 2020

Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan®

1 reference

12 December 2020

Identifiers

DOI

10.1038/AJG.2015.241

1 reference

30 September 2017

1 reference